Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - colecalciferol, quantity: 0.14 mg; alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; sucrose; butylated hydroxytoluene; croscarmellose sodium; microcrystalline cellulose; gelatin; medium chain triglycerides; colloidal anhydrous silica - alendronate plus d3 70 mg/140 microgram apotex are indicated for the treatment of: osteoporosis in select patients where vitamin d supplementation is recommended, prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - alendronate sodium monohydrate, quantity: 46.42 mg (equivalent: alendronic acid, qty 40 mg) - tablet, uncoated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; magnesium stearate - treatment of osteoporosis, including glucocorticoid induced osteoporosis. osteoporosis must be confirmed by the finding of low bone mass of at least two standard deviations below the gender specific mean for young adults or by the presence of history of osteoporotic fracture. paget's disease of bone.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - alendronate sodium monohydrate, quantity: 11.1 mg (equivalent: alendronic acid, qty 10 mg) - tablet, uncoated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; magnesium stearate - treatment of osteoporosis, including glucocorticoid induced osteoporosis. osteoporosis must be confirmed by the finding of low bone mass of at least two standard deviations below the gender specific mean for young adults or by the presence of history of osteoporotic fracture. paget's disease of bone.

United States - English - NLM (National Library of Medicine)

virtus pharmaceuticals - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronic acid 35 mg - alendronate sodium tablets, usp are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, alendronate sodium tablets, usp increase bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies (14.1).] alendronate sodium tablets, usp are indicated for the prevention of postmenopausal osteoporosis [see clinical studies (14.2)] . alendronate sodium tablets, usp are indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.3)] . alendronate sodium tablets, usp are indicat

United States - English - NLM (National Library of Medicine)

hangzhou minsheng binjiang pharmaceutical co., ltd. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronic acid 35 mg - alendronate sodium tablets, usp are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, alendronate sodium tablets, usp increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies (14.1).] alendronate sodium tablets, usp are indicated for the prevention of postmenopausal osteoporosis [see clinical studies (14.2)] . alendronate sodium tablets, usp are indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.3)] . alendronate sodium tablets, usp are indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucoc

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronic acid 35 mg - alendronate sodium tablets, usp are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, alendronate sodium tablets, usp increase bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies (14.1).] alendronate sodium tablets, usp are indicated for the prevention of postmenopausal osteoporosis [see clinical studies (14.2)] . alendronate sodium tablets, usp are indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.3)] . alendronate sodium tablets, usp are indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density [see clinical studie

Canada - English - Health Canada

angita pharma inc. - alendronic acid (alendronate sodium) - tablet - 70mg - alendronic acid (alendronate sodium) 70mg - bone resorption inhibitors

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg); colecalciferol, quantity: 0.07 mg - tablet, uncoated - excipient ingredients: gelatin; povidone; croscarmellose sodium; colloidal anhydrous silica; microcrystalline cellulose; medium chain triglycerides; butylated hydroxytoluene; magnesium stearate; sucrose - tradenames are indicated for the treatment of: ? osteoporosis* in select patients where vitamin d supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronic acid 70 mg - alendronate sodium tablets usp are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, alendronate sodium tablets usp increase bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures) [see clinical studies (14.1) ]. alendronate sodium tablets usp are indicated for the prevention of postmenopausal osteoporosis [see clinical studies (14.2) ]. alendronate sodium tablets usp are indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.3) ]. alendronate sodium tablets usp are indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density [see clinical studies (14.4) ]. alendronate sodium tablets usp are indicated for the treatment of paget’s disease of bone in men and women. treatment is indicated in patients with paget's di

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronate sodium tablets usp are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, alendronate sodium tablets usp increase bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures) [see clinical studies (14.1) ]. alendronate sodium tablets usp are indicated for the prevention of postmenopausal osteoporosis [see clinical studies (14.2) ]. alendronate sodium tablets usp are indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.3) ]. alendronate sodium tablets usp are indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density [see clinical studies (14.4) ]. alendronate sodium tablets usp are indicated for the treatment of paget’s disease of bone in men and women. treatment is indicated in patients with paget's di